MedPath

ACT: Avastin and Chemotherapy followed by Avastin alone or in combination with Tarceva for the treatment of metastatic colorectal cancer - ACT

Conditions
Patients with previously untreated metastatic colorectal carcinoma
Registration Number
EUCTR2006-002295-18-DK
Lead Sponsor
niversity Hospital, Dept of Oncology, clinical trial unit
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
182
Inclusion Criteria

Untreated metastatic colorectal carcinoma
Age = 18 years
Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST) criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Life expectancy more than 3 months
Adequate haematological, renal and liver function
Blood sample and paraffin embedded tumour tissue for translational research

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Adjuvant therapy within 6 months
Central nervous system (CNS) metastases
Clinically significant atherosclerotic vascular disease

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath